Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9478304 | 0.86 | LMNA (0.55) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL30585518 | 0.85 | RAB9A (0.49) | CYP3A4CYP2C9TSHRMAPTMEN1 | |
| SCHEMBL12742262 | 0.85 | LMNA (0.53) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL14402101 | 0.85 | LMNA (0.53) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL18566588 | 0.84 | LMNA (0.46) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL28884034 | 0.83 | LMNA (0.44) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL9506851 | 0.82 | LMNA (0.59) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL1714626 | 0.82 | LMNA (0.59) | LMNAKDM4EESR1CYP3A4SLC6A3 | |
| SCHEMBL18911104 | 0.81 | ACACB (0.54) | LMNATSHRMAPTALDH1A1MEN1 | |
| SCHEMBL1381830 | 0.81 | LMNA (0.43) | LMNAKDM4EESR1CYP3A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0590557-B1 | Process for preparing acetoxystyrene | BASF AG (DE) | 1996-08-14 | — | — | EP | claimed |
| US-5380918-A | Converting 1-(4-acetoxyphenyl)ethyl carboxylate with an acidic catalyst | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | claimed |
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | disclosed |
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | disclosed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | disclosed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | disclosed |
| WO-2009016565-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-05 | — | — | WO | disclosed |
| US-5380918-A | Converting 1-(4-acetoxyphenyl)ethyl carboxylate with an acidic catalyst | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
| US-5247124-A | Process for the preparation of substituted styrenes | HOECHST CELANESE CORPORATION (US) | 1993-09-21 | — | — | US | disclosed |
| US-5210278-A | Process for the preparation of bisarylalkyl ethers | HOECHST CELANESE CORPORATION (US) | 1993-05-11 | — | — | US | disclosed |
| US-5194672-A | Process for the preparation of substituted styrenes | HOECHST CELANESE CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL1R1, IL1B, IL1A | LMNA 1971/4885KDM4E 4136/4885ESR1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.